---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-22-002346"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T03:05:09.708316+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Zomedica reports 2021 full-year revenue of $4.1M; net loss $18.4M

## Summary
- Total revenue of $4.1M in 2021, vs $0 in 2020; gross margin 73.9%.
- Net loss $18.4M ($0.05 diluted EPS) vs $16.9M ($0.19) in 2020.
- PulseVet Q4 revenue $4.0M, up 66% YoY as standalone; TRUFORMA Q4 revenue $73k, up 224% QoQ.
- Cash and equivalents $195M at Dec 31, 2021 vs $62M a year earlier.
- Expected to launch eACTH assay in Q2 2022; evaluating M&A opportunities.

## SEC filing metadata
- accession: 0001654954-22-002346
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/0001654954-22-002346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495422002346/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-22-002346
- JSON: https://secwatch.observer/filing/0001654954-22-002346.json
- Plain text: https://secwatch.observer/filing/0001654954-22-002346.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.